Literature DB >> 27534868

[Catheter-based closure of the left atrial appendage : Stroke prevention in atrial fibrillation].

C Skurk1,2, D M Leistner1,2, J-W Park1, U Landmesser3,4,5.   

Abstract

In patients with nonvalvular atrial fibrillation, >90 % of thrombi are detected in the left atrial appendage (LAA). In particular these observations have resulted in the development of catheter-based LAA closure as an approach for stroke prevention in patients with nonvalvular atrial fibrillation in recent years. A preliminary randomized trial provided promising data with respect to efficacy and safety of this approach as compared to anticoagulation with warfarin. The safety of the procedure has been significantly improved in recent years due to procedural experience and refinement of implanted devices. In current clinical practice, this approach is particularly used for patients with nonvalvular atrial fibrillation, a significant ischemic risk (CHA2DS2-VASc score ≥2), and a high bleeding risk, i. e., in patients in whom there are relevant concerns with respect to long-term anticoagulation. The present article discusses the data from randomized clinical studies and registries, the present guideline recommendations, and the practical clinical use of LAA closure for stroke prevention.

Entities:  

Keywords:  Anticoagulants, oral; Atrial fibrillation, nonvalvular; Platelet aggregation inhibitors; Risk, hemorrhage; Thromboembolism

Mesh:

Year:  2016        PMID: 27534868     DOI: 10.1007/s00108-016-0113-z

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  30 in total

1.  Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis.

Authors:  Mitesh Shah; Meytal Avgil Tsadok; Cynthia A Jackevicius; Vidal Essebag; Mark J Eisenberg; Elham Rahme; Karin H Humphries; Jack V Tu; Hassan Behlouli; Helen Guo; Louise Pilote
Journal:  Circulation       Date:  2014-01-22       Impact factor: 29.690

2.  Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation.

Authors:  Albert L Waldo; Richard C Becker; Victor F Tapson; Kevin J Colgan
Journal:  J Am Coll Cardiol       Date:  2005-10-10       Impact factor: 24.094

3.  Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry.

Authors:  Vivek Y Reddy; David Holmes; Shephal K Doshi; Petr Neuzil; Saibal Kar
Journal:  Circulation       Date:  2011-01-17       Impact factor: 29.690

4.  Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.

Authors:  David R Holmes; Saibal Kar; Matthew J Price; Brian Whisenant; Horst Sievert; Shephal K Doshi; Kenneth Huber; Vivek Y Reddy
Journal:  J Am Coll Cardiol       Date:  2014-07-08       Impact factor: 24.094

5.  Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial.

Authors:  David R Holmes; Vivek Y Reddy; Zoltan G Turi; Shephal K Doshi; Horst Sievert; Maurice Buchbinder; Christopher M Mullin; Peter Sick
Journal:  Lancet       Date:  2009-08-15       Impact factor: 79.321

6.  Left atrial appendage closure with the Amplatzer cardiac plug in patients with atrial fibrillation.

Authors:  Enio Eduardo Guérios; Michael Schmid; Steffen Gloekler; Ahmed A Khattab; Peter M Wenaweser; Stephan Windecker; Bernhard Meier
Journal:  Arq Bras Cardiol       Date:  2012-05-15       Impact factor: 2.000

7.  Does the left atrial appendage morphology correlate with the risk of stroke in patients with atrial fibrillation? Results from a multicenter study.

Authors:  Luigi Di Biase; Pasquale Santangeli; Matteo Anselmino; Prasant Mohanty; Ilaria Salvetti; Sebastiano Gili; Rodney Horton; Javier E Sanchez; Rong Bai; Sanghamitra Mohanty; Agnes Pump; Mauricio Cereceda Brantes; G Joseph Gallinghouse; J David Burkhardt; Federico Cesarani; Marco Scaglione; Andrea Natale; Fiorenzo Gaita
Journal:  J Am Coll Cardiol       Date:  2012-08-07       Impact factor: 24.094

8.  Edoxaban versus warfarin in patients with atrial fibrillation.

Authors:  Robert P Giugliano; Christian T Ruff; Eugene Braunwald; Sabina A Murphy; Stephen D Wiviott; Jonathan L Halperin; Albert L Waldo; Michael D Ezekowitz; Jeffrey I Weitz; Jindřich Špinar; Witold Ruzyllo; Mikhail Ruda; Yukihiro Koretsune; Joshua Betcher; Minggao Shi; Laura T Grip; Shirali P Patel; Indravadan Patel; James J Hanyok; Michele Mercuri; Elliott M Antman
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245

9.  Left atrial appendage morphology in patients with suspected cardiogenic stroke without known atrial fibrillation.

Authors:  Miika Korhonen; Antti Muuronen; Otso Arponen; Pirjo Mustonen; Marja Hedman; Pekka Jäkälä; Ritva Vanninen; Mikko Taina
Journal:  PLoS One       Date:  2015-03-09       Impact factor: 3.240

10.  Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry.

Authors:  Ajay K Kakkar; Iris Mueller; Jean-Pierre Bassand; David A Fitzmaurice; Samuel Z Goldhaber; Shinya Goto; Sylvia Haas; Werner Hacke; Gregory Y H Lip; Lorenzo G Mantovani; Alexander G G Turpie; Martin van Eickels; Frank Misselwitz; Sophie Rushton-Smith; Gloria Kayani; Peter Wilkinson; Freek W A Verheugt
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

View more
  1 in total

Review 1.  Systematic review on left atrial appendage closure with the LAmbre device in patients with non-valvular atrial fibrillation.

Authors:  Muhammad Ali; Angelos G Rigopoulos; Mammad Mammadov; Abdelrahman Torky; Andrea Auer; Marios Matiakis; Elena Abate; Constantinos Bakogiannis; Stergios Tzikas; Boris Bigalke; Daniel Sedding; Michel Noutsias
Journal:  BMC Cardiovasc Disord       Date:  2020-02-12       Impact factor: 2.298

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.